Altimmune (NASDAQ:ALT) Stock

Altimmune

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Altimmune Inc

AltLayer - United States Dollar

ALT11M2507 - United States Dollar

ALT11M250830 - United States Dollar

ALT11M251029 - United States Dollar

ALT2612 - United States Dollar

Morella Corp Ltd

ALPINE AUTO BROKERS INC by Alpine Auto Brokers Inc

Alpine Auto Brokers Inc

ALTURAS MINERALS CORP by Alturas Minerals Corp.

Alturas Minerals Corp

ALTITUDE INTL INC by Altitude International Holdings, Inc.

Altitude International Holdings Inc

Alta Equipment Group Inc. Class A Common Stock

Alta Equipment Group Inc

Alta Equipment Group Inc. Depositary Shares (each representing 1/1000th in a share of 10% Series A Cumulative Perpetual Preferred Stock)

ALTECH CHEMICALS LTD by Altech Chemicals Ltd.

Altech Batteries Ltd

AlTi Global Inc

Pacer Lunt Large Cap Alternator ETF

ARCADIUM LITHIUM PLC SHS

Kinetik Holdings Inc Warrants (09/11/2023)

ALTERNUS ENERGY GROUP PLC by ALTERNUS ENERGY GROUP PLC.

Alternus Energy Group PLC

Alto Ingredients Inc

ALTIPLANO METALS INC ORD by Altiplano Metals Inc.

Altiplano Metals Inc

Altair Engineering Inc. - Class A Common Stock

Altair Engineering Inc

ALT5 Sigma Corp

Altitude Acquisition Corp Ordinary Shares - Class A

Altitude Acquisition Corp

Altitude Acquisition Corp Units (1 Ord Share Class A & 1/2 War)

Altitude Acquisition Corp Warrants (30/11/2027)

ALTEX INDUS INC by Altex Industries, Inc.

Altex Industries Inc

Global X Alternative Income ETF

WIIM

Altimmune shares are trading higher amid rumours several large pharmaceutical organizations are interested in the company.

News

Rumors

Trading Ideas

Watching Altimmune; Traders Circulate M&A Blog Comments Suggesting Multiple Large Pharma Co's Interested In The Company

Citizens Capital Markets analyst Jonathan Wolleben reiterates Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) with a Market Outperform and maintains $25 price target.

Price Target

Reiteration

Analyst Ratings

Citizens Capital Markets Reiterates Market Outperform on Altimmune, Maintains $25 Price Target

Altimmune Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) hosted a virtual R&amp;D day on Thursday, marking the first disclosure of Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD) as potential developments <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">for pemvidutide</a>.
Phase 2 trials for pemvidutide in AUD and ALD are expected to start in the second and third quarters of 2025, respectively.
Altimmune <a href="https://investorday.altimmune.com/presentation" target="_blank" rel="noreferrer noopener">anticipates</a> pemvidutide will reduce alcohol cravings, improve liver health and promote weight loss.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41296978/novo-nordisk-eli-lilly-could-face-downward-pressure-despite-market-dominance-from-p" rel="noreferrer noopener">Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names</a>
<ul>
<li>The primary <a href="https://investorday.altimmune.com/static-files/95c517e2-36ee-4427-9278-2d87cc4c1460" target="_blank" rel="noreferrer noopener">endpoint</a> for the Phase 2 ALD study will be a change in liver stiffness measurement at 24 weeks, with other key endpoints of weight loss and change in alcohol consumption, with an additional <a href="https://www.benzinga.com/news/24/06/39456224/altimmune-stock-is-rising-monday-whats-driving-the-action" target="_blank" rel="noreferrer noopener">reading at 48 weeks</a>.</li>
<li>The primary endpoint of the Phase 2 AUD study will be the change in the number of heavy drinking days at 24 weeks and the change in biomarkers of alcohol consumption and weight loss as secondary endpoints.</li>
</ul>
William Blair writes, &#8220;In our view, AUD and ALD are logical extensions for evaluation of pemvidutide&#8217;s efficacy, given its mechanisms of action.&#8221;
Altimmune shared the MOMENTUM Phase 2 trial data summary during the presentation, showing that over 30% of subjects lost ≥ 20% of body weight on pemvidutide 2.4 mg dose.
<ul>
<li>The lean mass ratio of lean body mass weight loss to total weight loss was 21.9% for pemvidutide in the Phase 2 MOMENTUM study, compared to 39.9% for semaglutide (based on Phase 3 STEP-1 trial data), 37.7% for retatrutide (from the Phase 2 study), and 26% for tirzepatide in the Phase 3 SURMOUNT 1 trial.</li>
</ul>
Novo Nordisk A/S&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) semaglutide is available as Wegovy and Ozempic and Eli Lilly And Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) is available as Zepbound and Mounjaro.
The company says Phase 2b IMPACT trial results of pemvidutide for MASH are expected in the second quarter, and if successful, pemvidutide would become:
<ul>
<li>The first incretin-based agent to achieve statistical significance on fibrosis improvement at 24 weeks.</li>
<li>The first therapeutic candidate in any class to achieve statistically significant fibrosis improvement and meaningful weight loss at 24 weeks.</li>
<li>Altimmune expects to start registrational Phase 3 study in MASH in the first half of 2026</li>
</ul>
The presentation highlighted that at 24 weeks in the Phase 1b trial in metabolic dysfunction-associated steatotic liver disease (MASLD), pemvidutide demonstrated a 76.4% relative reduction in liver fat at the highest 2.4 mg dose (compared to 14% for placebo).
ALT Price Action: ALT stock is up 4.71% at $5.45 at publication Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44312852/needham-downgrades-dental-players-dentsply-sirona-zimvie-citing-weak-growth-outlook" target="_blank" rel="noreferrer noopener">Dental Players Dentsply Sirona, ZimVie Show Weak Growth Outlook: Analyst</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

General

Altimmune Expands Weight-Loss Drug Pemvidutide's Potential To Alcohol-Related Disorders

Ratings for Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $13.5, a high estimate of $18.00, and a low estimate of $12.00. This current average has increased by 12.5% from the previous average price target of $12.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1741035645_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of Altimmune by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Annabel Samimy</td>
<td>Stifel</td>
<td>Announces</td>
<td>Buy</td>
<td>$18.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Altimmune. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Altimmune compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Altimmune's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Altimmune's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ALT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Altimmune analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Altimmune Better</h2>
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
<h3>A Deep Dive into Altimmune's Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Challenges: Altimmune's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -98.62%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Altimmune's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -456900.0%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Altimmune's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -15.98% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Altimmune's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -14.22%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Altimmune's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) with a Buy and maintains $12 price target.

HC Wainwright & Co. Reiterates Buy on Altimmune, Maintains $12 Price Target

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>William Blair analyst Andy Hsieh initiated coverage on Altimmune, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) with a Market Perform rating. Altimmune shares closed at $6.42 on Thursday. <a href="https://www.benzinga.com/quote/alt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Craig-Hallum analyst Chase Knickerbocker initiated coverage on MediWound Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) with a Buy rating and announced a price target of $39. MediWound shares closed at $16.23 on Thursday. <a href="https://www.benzinga.com/quote/mdwd/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank analyst Faiza Alwy initiated coverage on CoStar Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGP#NASDAQ">CSGP</a>) with a Buy rating and announced a price target of $89. CoStar Group shares closed at $74.36 on Thursday. <a href="https://www.benzinga.com/quote/csgp/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Salveen Richter initiated coverage on Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) with a Buy rating and announced a price target of $42. Summit Therapeutics shares closed at $18.49 on Thursday. <a href="https://www.benzinga.com/quote/smmt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Yasmeen Rahimi initiated coverage on Avalo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>) with an Overweight rating and announced a price target of $48. Avalo Therapeutics shares closed at $6.60 on Thursday. <a href="https://www.benzinga.com/quote/avtx/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/44018351/top-3-utilities-stocks-you-may-want-to-dump-in-february">Top 3 Utilities Stocks You May Want To Dump In February</a></li>
</ul>

Initiation

Markets

AVTX

CSGP

MDWD

SMMT

This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

William Blair analyst Andy Hsieh initiates coverage on Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) with a Market Perform rating.

William Blair Initiates Coverage On Altimmune with Market Perform Rating

Altimmune shares are trading higher. The company reported Q4 financial results.

Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) reported quarterly losses of $(0.33) per share which met the analyst consensus estimate. This is a 38.89 percent increase over losses of $(0.54) per share from the same period last year. The company reported $5.00 thousand in sales this quarter. This is a 86.49 percent decrease over sales of $37.00 thousand the same period last year.

Earnings

Altimmune Q4 2024 GAAP EPS $(0.33), Inline, Sales $5.00K Down From $37.00K YoY, Cash, Cash Equivalents And Short-term Investments Of $131.9M

AAON

ABCL

ACEL

ACHC

ACHR

ACIC

ACIW

ADSK

AIRG

ALEX

ALHC

ALKT

ALTM

AMBP

AMPH

AMRC

AMWD

ARGX

ARLO

ARRY

ASTH

AUPH

AVPT

BBWI

BCSF

BECN

BLND

BWMX

CABO

CARS

CCOI

CDXS

CLCO

CLOV

CMBT

CMLS

CMPS

CODI

COLL

CRDF

CRNX

CRON

CSTL

CTKB

CUBE

CVEO

CYTK

DAIO

DCGO

DELL

DUOL

ECVT

EFXT

ERIE

Embraer-Empresa Brasileira De Aeronautica

ESEA

ESTC

EVRG

EXFY

FIGS

FOXF

FTDR

FWONA

FWONK

GBTG

GDEN

GDOT

GDRX

Earnings Scheduled For February 27, 2025

Throughout the last three months, 4 analysts have evaluated Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $17.0, a high estimate of $26.00, and a low estimate of $12.00. This upward trend is apparent, with the current average reflecting a 41.67% increase from the previous average price target of $12.00.
<img src="https://www.benzinga.com/files/images/story/2025/1737637245_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Altimmune among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Annabel Samimy</td>
<td>Stifel</td>
<td>Announces</td>
<td>Buy</td>
<td>$18.00</td>
<td>-</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$26.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Altimmune. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Altimmune compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Altimmune's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Altimmune's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ALT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Altimmune analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Altimmune</h2>
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
<h3>Altimmune's Financial Performance</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Decline in Revenue: Over the 3 months period, Altimmune faced challenges, resulting in a decline of approximately -98.62% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Altimmune's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -456900.0%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Altimmune's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -15.98%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Altimmune's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -14.22%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Altimmune's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Barclays analyst Paul Kearney initiated coverage on Levi Strauss &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) with an Overweight rating and announced a price target of $24. Levi Strauss shares closed at $17.67 on Tuesday. <a href="https://www.benzinga.com/quote/levi/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities analyst Asthika Goonewardene initiated coverage on Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) with a Buy rating and announced a price target of $35. Summit Therapeutics shares closed at $18.16 on Tuesday. <a href="https://www.benzinga.com/quote/SMMT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel analyst Annabel Samimy initiated coverage on Altimmune, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) with a Buy rating and announced a price target of $18. Altimmune shares closed at $7.31 on Tuesday. <a href="https://www.benzinga.com/quote/alt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B. Riley Securities analyst Mayank Mamtani initiated coverage on Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) with a Buy rating and announced a price target of $4. Nektar Therapeutics shares closed at $1.19 on Tuesday. <a href="https://www.benzinga.com/quote/nkKR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JMP Securities analyst Silvan Tuerkcan initiated coverage on Context Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTX#NASDAQ">CNTX</a>) with a Market Outperform rating and announced a price target of $4. Context Therapeutics shares closed at $1.09 on Tuesday. <a href="https://www.benzinga.com/quote/cntx/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying LEVI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="587" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08073956/image-46-1024x587.png" alt="" class="wp-image-723832" style="width:553px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08073956/image-46-1024x587.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08073956/image-46-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08073956/image-46-768x440.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08073956/image-46.png 1117w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/01/42846607/bank-of-new-york-mellon-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Bank of New York Mellon Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>

Pre-Market Outlook

CNTX

LEVI

NKTR

This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Stifel analyst Annabel Samimy initiates coverage on Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) with a Buy rating and announces Price Target of $18.

Stifel Initiates Coverage On Altimmune with Buy Rating, Announces Price Target of $18

Altimmune Will Be Added To The Nasdaq Biotechnology Index Effective Prior To The Market Open On December 23, 2024

Deep-pocketed investors have adopted a bearish approach towards Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ALT usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 13 extraordinary options activities for Altimmune. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 38% leaning bullish and 53% bearish. Among these notable options, 2 are puts, totaling $76,800, and 11 are calls, amounting to $506,795.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $5.0 to $15.0 for Altimmune over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Altimmune's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Altimmune's whale activity within a strike price range from $5.0 to $15.0 in the last 30 days. 
<h3>Altimmune Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733339802_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/27/24</td>
<td>$3.6</td>
<td>$3.4</td>
<td>$3.4</td>
<td>$7.00</td>
<td>$102.0K</td>
<td>315</td>
<td align="right">307</td>
</tr>
<tr>
<td>ALT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$7.4</td>
<td>$7.2</td>
<td>$7.25</td>
<td>$5.00</td>
<td>$72.4K</td>
<td>335</td>
<td align="right">100</td>
</tr>
<tr>
<td>ALT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$5.8</td>
<td>$5.5</td>
<td>$5.74</td>
<td>$5.00</td>
<td>$45.9K</td>
<td>68</td>
<td align="right">85</td>
</tr>
<tr>
<td>ALT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$2.15</td>
<td>$2.0</td>
<td>$2.15</td>
<td>$11.00</td>
<td>$43.0K</td>
<td>355</td>
<td align="right">201</td>
</tr>
<tr>
<td>ALT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$4.8</td>
<td>$4.0</td>
<td>$4.0</td>
<td>$10.00</td>
<td>$40.0K</td>
<td>3.6K</td>
<td align="right">100</td>
</tr>
</tbody>
</table>

<h3>About Altimmune</h3>
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
Following our analysis of the options activities associated with Altimmune, we pivot to a closer look at the company's own performance.
<h3>Current Position of Altimmune</h3>
<ul>
<li>With a volume of 8,911,145, the price of ALT is up 14.11% at $10.03. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 112 days.</li>
</ul>
<h3>Expert Opinions on Altimmune</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $19.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from HC Wainwright &amp; Co. lowers its rating to Buy with a new price target of $12. 
&#x2A; An analyst from UBS downgraded its action to Buy with a price target of $26. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Altimmune options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Looking At Altimmune's Recent Unusual Options Activity

U.S. stocks were higher, with the Dow Jones index gaining more than 150 points on Wednesday.
Shares of Pure Storage Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTG#NYSE">PSTG</a>) gained 26.1% to $67.48 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter <a href="https://www.benzinga.com/news/earnings/24/12/42303442/pure-storage-shares-soar-after-strong-q3-q4-guidance-above-estimates-details">guidance above estimates</a>.
Pure Storage reported quarterly earnings of 50 cents per share, which beat the analyst consensus estimate of 42 cents. Quarterly revenue came in at $831.07 million which beat the consensus estimate of $818.14 million and is an increase over sales of $762.84 million from the same period last year.
Pure Storage shares jumped 26.1% to $67.48 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Cross Country Healthcare, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) shares gained 61.9% to $18.07 after Aya Healthcare announced a definitive agreement to acquire the company for approximately $615 million.</li>
<li>Altimmune Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) surged 22.4% to $10.76.</li>
<li>Marvell Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) climbed 22% to $117.05 as the company reported better-than-expected third-quarter financial results and issued fourth-quarter guidance above estimates on Tuesday.</li>
<li>Hesai Group – ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) gained 20.6% to $9.65.</li>
<li>Stoke Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>) jumped 15.2% to $13.17 after the company announced it received breakthrough therapy designation status from the FDA for Zorevuvnersen.</li>
<li>Navitas Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) rose 15.1% to $3.6150.</li>
<li>Bitdeer Technologies Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) climbed 14.6% to $16.97.</li>
<li>MaxLinear, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXL#NASDAQ">MXL</a>) gained 14.2% to $19.85.</li>
<li>Microvast Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) gained 14.2% to $1.61.</li>
<li>Zeta Global Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NASDAQ">ZETA</a>) rose 13.3% to $27.10 after the company announced a 106% year-over-year usage increase for its marketing platform from Thanksgiving to Cyber Monday.</li>
<li>SoundHound AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) gained 12.4% to $9.99.</li>
<li>Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) rose 10.2% to $83.41. Needham maintained a Buy rating on the stock.</li>
<li>Salesforce, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) gained 9.2% to $362.05 following third-quarter results.</li>
<li>Powell Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>) surged 8.8% to $292.50.</li>
<li>UiPath Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) rose 8.5% to $15.61.</li>
<li>JetBlue Airways Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) gained 7.2% to $6.49.</li>
<li>MongoDB, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) rose 6.6% to $345.27 after Baird maintained an Outperform rating on the stock and raised its price target from $305 to $380.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42314096/att-to-rally-around-14-here-are-10-top-analyst-forecasts-for-wednesday">AT&amp;T To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday</a></li>
</ul>

Intraday Update

Movers

BTDR

CCRN

HSAI

JBLU

MRVL

MVST

NVTS

PATH

POWL

PSTG

ROKU

SOUN

STOK

ZETA

Pure Storage Posts Upbeat Results, Joins Cross Country Healthcare, Marvell Technology, Stoke Therapeutics And Other Big Stocks Moving Higher On Wednesday

Weekly subcutaneous doses of pemvidutide resulted in robust reductions in cardio-inflammatory, hepato-inflammatory and atherosclerotic lipids
Findings support the potential benefit of pemvidutide on co-morbidities of metabolic dysfunction-associated steatohepatitis (MASH), including atherosclerosis, heart disease and metabolic syndrome
Pemvidutide is currently being evaluated in IMPACT, the Phase 2b trial in subjects with MASH; data readout expected in Q2 2025
GAITHERSBURG, Md., Nov. 15, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=8mpdWoq0vRuruY-wgKR7jeGdXm_k2idcer7Db_E2cxWdj4yekH1YRRXMjYkm08SS2fPpYVFEMZXywtJ8hQ3K1A==">Altimmune, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), a clinical-stage biopharmaceutical company, today presented new data from its 12-week Phase 1b trial of pemvidutide in metabolic dysfunction-associated steatotic liver disease (MASLD) at The Liver Meeting&#xAE; of the&nbsp;American Association for the Study of Liver Diseases. The data showed reductions in multiple classes of inflammatory lipid species associated with adverse cardiovascular outcomes. Pemvidutide is a balanced GLP-1/glucagon dual receptor agonist in development for the treatment of MASH and obesity.
The new data were derived from an analysis of plasma samples from subjects who completed a randomized placebo-controlled Phase 1b trial of pemvidutide in subjects with overweight or obesity and MASLD. In the Phase 1b clinical trial, 94 subjects with obesity or overweight and liver fat content (LFC) ≥10% were dosed 1:1:1:1 to pemvidutide (1.2mg, 1.8mg and 2.4mg) or placebo administered once-weekly subcutaneously for 12 weeks. In this study, pemvidutide reduced LFC relative to baseline by up to 68.5% and decreased total cholesterol and triglycerides by up to 12.2% and 44.6%, respectively, after 12 weeks of treatment.
The goal of the study was to characterize changes in the lipid profile of patients before and after treatment with pemvidutide. In this study of 50 subjects, treatment with pemvidutide was shown to reduce plasma concentrations of atherogenic lipoproteins and lipotoxic lipid classes associated with MASH and implicated in cardiovascular and atherosclerotic disease. In particular, a rapid and significant reduction in small atherogenic LDL particles was observed in the 1.8 mg and 2.4 mg dose groups compared to placebo.

Altimmune Presents New Data On The Effect Of Pemvidutide On Inflammatory Lipids In Subjects With Metabolic Dysfunction-Associated Steatotic Liver Disease At The Liver Meeting 2024

Press Releases

Altimmune to Participate at Two Upcoming Investor Conferences

Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders

Altimmune Added to Nasdaq Biotechnology Index

Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference

Legal

Sprout Social, Altimmune, Equinix, and Globe Life Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information

Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025

Management

Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors

Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Comments

Altimmune

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL